Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses The CLARITY Trial Lead by Dr. Hillmen Feasibility study that looked at efficacy of Ibrutnib and Venetolax in RR-CLL at MOASCs Spotlight On Hematology in Huntington Beach 2018.
The CLARITY Trial Lead by Dr. Hillmen Feasibility study that looked at efficacy of Ibrutnib and Venetolax in RR-CLL
